Optimizing dosing strategies for children with leprosy: A weight-banded dosing approach
Background: Dosing guidance for children with leprosy remains operationally challenging. For children under 10 years of age, current WHO recommendations rely on mg/kg dosing of the three separate components of leprosy multidrug therapy, which are difficult to implement in routine care and may result in inconsistent drug exposures. Weight-banded dosing offers a pragmatic alternative that better aligns with pharmacokinetic principles and existing drug formulations. Methodology: A pharmacokinetic simulation study was conducted to develop harmonized weight-banded dosing regimens for rifampicin, clofazimine, and dapsone in children aged 2 to <10 years. Using the WHO dosing tool, drug exposures across harmonized weight bands were simulated and adult-equivalent systemic exposure (80-125% of adult area under the concentration-time curve) targeted. Predicted exposures were contextualized against safety reference regimens used in tuberculosis meningitis, multidrug-resistant tuberculosis, and leprosy. An iterative review process involving the WHO Technical Working Group on leprosy in children ensured clinical and operational feasibility. Results: Proposed weight-banded multidrug therapy regimens achieved adult-equivalent exposures across most weight bands. Predicted exposures modestly exceeded 125% of adult levels at the lower end of selected weight bands but remained well below safety benchmarks, namely exposures associated with daily rifampicin therapy for tuberculosis meningitis and clofazimine regimens for multidrug-resistant tuberculosis. Dapsone exposures were comparable to those achieved with current leprosy dosing. The existing 10-14-year-old child MDT blister pack could be used without modification in children weighing 25-39.9 kg and with limited tablet or gel capsule removal in children weighing 6-24.9 kg. Conclusions: A harmonized weight-banded dosing strategy was developed that enables effective, practical dosing of leprosy multidrug therapy in children under 10 years using existing free-of-charge blister packs provided through WHO. This approach improves dosing consistency, supports programmatic implementation, and provides a rational interim solution while child-friendly formulations are being developed.
Authors
- Becks Hill (ORCID: https://orcid.org/0009-0001-6300-352X)
- Wim H. van Brakel (ORCID: https://orcid.org/0000-0002-0277-2907)
- Maurício Lisboa Nobre (ORCID: https://orcid.org/0000-0003-4932-3137)
- Sushant Satish Mane
- Tiziana Masini (ORCID: https://orcid.org/0000-0003-0400-1919)
- Patrícia D. Deps (ORCID: https://orcid.org/0000-0002-9707-1934)
- Joydeepa Darlong (ORCID: https://orcid.org/0000-0002-3242-8875)
- Roeland E. Wasmann (ORCID: https://orcid.org/0000-0002-5769-8150)
- Saba M. Lambert (ORCID: https://orcid.org/0000-0003-4376-5495)
- Vivek Lal (ORCID: https://orcid.org/0000-0001-7050-1183)
- Jennie van Dyk (ORCID: https://orcid.org/0000-0003-0085-8667)
- Parul Malik
- Amar Bahadur Timalsina
- Sunil Arkar Modali
Institutions
- University of London (GB)
- University of Cape Town (ZA)
- Grant Medical College and Sir Jamshedjee Jeejeebhoy Group of Hospitals (IN)
- The Leprosy Mission International (GB)
- Instituto Federal do Rio Grande do Norte (BR)
- Universidade Federal do Rio Grande do Norte (BR)
- London School of Hygiene & Tropical Medicine (GB)
- Grande International Hospital (NP)
- World Health Organization (CH)
- Novartis (United Kingdom) (GB)
- European Consortium for Political Research (GB)
- The Leprosy Mission Trust India (IN)
- Universidade Federal do Espírito Santo (BR)
- Colchester Institute (GB)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-12
- DOI
- https://doi.org/10.64898/2026.11.11.26367824
- Primary Topic
- Leprosy Research and Treatment
- Type
- preprint
Funders
- World Health Organization